http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014511924-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L101-16 |
| filingDate | 2012-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2014511924-A |
| titleOfInvention | Biocompatible polycaprolactone fumarate |
| abstract | Polycaprolactone fumarate polymers useful as matrix materials for biocompatible scaffolds for tissue manipulation are described. A polycaprolactone fumarate polymer is produced by reacting caprolactone with an alkane polyol to produce a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to produce a polycaprolactone fumarate polymer. Can be obtained. Linear polycaprolactone diol precursors can be prepared by using alkane diols such as 1,2-propanediol. Branched polycaprolactone triol precursors can be prepared by using alkanetriols, such as glycerol. Biocompatible polycaprolactone fumarate formulations do not release diethylene glycol or other unwanted by-products upon degradation. |
| priorityDate | 2011-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.